BusinessClinical Cancer Research Publishes Phase I Data from a Study of Rafael Pharmaceuticals' Lead CPI-613 Compound in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid LeukemiaBy Nasdaq OMXApr 12, 2018, 3:00 PM UTC
BusinessRafael Pharmaceuticals, in Collaboration with Atlantic Health System, Announces Initiation of a Phase I Study of CPI-613 in Combination with Gemcitabine and Nab-Paclitaxel for Patients with Locally Advanced or Metastatic Pancreatic CancerBy Nasdaq OMXNov 16, 2017, 2:24 PM UTC
BusinessRafael Pharmaceuticals to Present Late Breaking Data at the 2017 European Society for Medical Oncology (ESMO) Annual MeetingBy Nasdaq OMXSep 8, 2017, 11:00 AM UTC
BusinessThe Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic CancerBy Nasdaq OMXMay 9, 2017, 3:15 PM UTC
